Affinity biosensor for point-of-care diagnostics
JHU Ref #: C17711
Value Proposition:
· Highly sensitive biosensor that uses quantum plexcitons to detect a variety of biological analytes at extremely low concentrations
· Greater specificity than industry leading surface plasmon resonance and quartz crystal microbalance technologies
· Can be packaged into point-of-care diagnostic for field-deployable rapid detection of analyte panels
· Does not require expensive instrumentation
Technology Description
· Researchers at Johns Hopkins have developed a broadly generalizable quantum plexcitonic method for molecular sensing of analytes at extremely low concentrations. Quantum plexcitons enable increased sensitivity due to generation of two spectral peaks as opposed to the single peak seen in surface plasmon resonance technology. The spectral peaks generated by plexcitons are more sensitive and provide more information about the analytes present which enables this technology to be used as an ultrasensitive, accurate biosensor for disease diagnosis.
Unmet Need
· Surface plasmon resonance is the predominant technology used for optical biosensing in diagnostic settings, biomedical research, and drug discovery.
· SPR is limited by the concentration and molecular size of molecules and technical limitations like complicated set-up/analysis and inability to perform high throughput testing.
· Therefore, there is a strong need for alternate optical biosensing technologies that offer highly sensitive detection of disease biomarkers and molecular interactions for disease diagnostics.
Stage of Development
· Proof of concept
Publication
Zheng, P., Semancik, S., & Barman, I. (2023). Quantum plexcitonic sensing. Nano Letters, 23(20), 9529-9537.
